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Oxidative stress plays a crucial role in the pathogenesis of retinal ischemia/hypoxia, a complication of ocular diseases such as
diabetic retinopathy (DR) and retinopathy of prematurity (ROP). Oxidative stress refers to the imbalance between the production
of reactive oxygen species (ROS) and the ability to scavenge these ROS by endogenous antioxidative systems. Free radicals and
ROS are implicated in the irreversible damage to cell membrane, DNA, and other cellular structures by oxidizing lipids, proteins,
and nucleic acids. Anti-oxidants that can inhibit the oxidative processes can protect retinal cells from ischemic/hypoxic insults. In
particular, treatment using anti-oxidants such as vitamin E and lutein, inhibition of nicotinamide adenine dinucleotide phosphate
oxidase (NADPH oxidase) or related signaling pathways, and administration of catalase and superoxide dismutase (SOD) are
possible therapeutic regimens for DR, ROP, and other retinal ischemic diseases. The role of oxidative stress in the pathogenesis of
DR and ROP as well as the underlying mechanisms involved in the hypoxia/ischemia-induced oxidative damage is discussed. The
information provided will be beneficial in understanding the underlying mechanisms involved in the pathogenesis of the diseases
as well as in developing effective therapeutic interventions to treat oxidative stress-induced damages.
1. Introduction
The retina is highly susceptible to oxidative damage by
reactive oxygen species (ROS). Besides having the highest
oxygen consumption in the body [1], the retina is also
prone to photo-oxidation due to its constant exposure to
incoming light. The high oxygen consumption and endless
light exposure in the retina may in turn generate ROS.
Moreover, the high lipid content in the retina (due to
abundant polyunsaturated fatty acids in the photoreceptor
outer segment) makes it prone to lipid peroxidation. Dur-
ing pathological conditions such as retinal ischemia, the
imbalance between the production of ROS and the ability
to scavenge these ROS by endogenous antioxidant systems is
exaggerated. ROS triggers several signaling pathways, affects
DNA and lipids inside the cell, and subsequently leads to cell
death. Antioxidants that can inhibit or prevent the oxidative
processes can protect retinal cells from ischemic damage.
2. Sources of Oxidants
A free radical is an atom, a molecule, or an ion having
unpaired electrons. Due to the presence of the “free” electron
in the outer shell, free radical is chemically very unstable and
reactive. In order to achieve stability, free radical will par-
ticipate in further reduction and oxidation reactions. There-
fore, production of one free radical leads to further radical
formation via sequential chain reactions [2]. Free radicals
that are derived from oxygen are ROS, being one of the major
contributors of oxidative stress. They include superoxide
anion (O2
−), perhydroxyl radical (also known as hydroper-
oxyl radical, HO2), and hydroxyl radical (OH). Superoxide
is formed by either the enzymatic reduction of oxygen
by nicotinamide adenine dinucleotide phosphate oxidase
(NADPH oxidase) or nonenzymatic reaction of mitochon-
drial respiration [3]. It is converted into hydrogen peroxide
(H2O2) enzymatically by superoxide dismutase (SOD) or
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nonenzymatically to H2O2 and singlet oxygen [3, 4]. Singlet
oxygen is a powerful oxidant and is able to oxidize lipids,
proteins and nucleic acids [5]. Perhydroxyl radical is the
protonated form of superoxide, acting as an oxidant and
reacts with polyunsaturated fatty acids in the membrane
lipid bilayer, thereby initiating lipid peroxidation. Hydroxyl
radical is another reactive radical which can be formed either
from the reaction of singlet oxygen and H2O2 by the Haber-
Weiss reaction [6] or from the interaction between H2O2
and reduced transition metals such as ferrous ions by the
Fenton reaction [3, 6, 7]. Generation of superoxide, singlet
oxygen and hydroxyl radical causes detrimental effects on the
physiological states of cells by cleaving covalent bonding in
protein and carbohydrates, leading to lipid peroxidation and
compromising the integrity of cell membrane [3, 6, 7].
Another free radical, nitric oxide (NO) is generated
from the oxidation of the guanidine group of L-arginine
catalyzed by the enzyme nitric oxide synthase (NOS). NO
is in fact a signaling molecule. Moreover, NO can react
with superoxide to from a strong oxidant, peroxynitrite
(ONOO), one of the reactive nitrogen species (RNS). Similar
to ROS, excessive production of RNS (nitrosative stress)
results in nitrosylation, causing deleterious effects such as
lipid peroxidation, DNA damage and SOD inactivation [8].
Therefore, the toxic effects of ONOO and NO should also be
taken into account in developing the antioxidative strategy
[9].
3. Anti-Oxidative Mechanisms and
Oxidative Stress
In physiological condition, ROS and RNS are products of
normal cellular metabolism. ROS can be efficiently scav-
enged by the intrinsic antioxidant defense mechanisms.
Manganese superoxide dismutase (MnSOD), copper/zinc
superoxide dismutase (Cu/Zn SOD), catalase, and glutathi-
one peroxidase (GPx) are members of the enzymatic antioxi-
dants while ascorbic acid (vitamin C), α-tocopherol (vitamin
E), glutathione (GSH), and β-carotene are nonenzymatic
antioxidants. For example, MnSOD and Cu/Zn SOD convert
superoxide to H2O2, which is then efficiently changed to
water by GPx or catalase [10, 11]. On the other hand, vitamin
E, vitamin C and β-carotene act as radical scavengers.
Vitamin E also reduces and removes lipid peroxyl radical, a
product of the reaction between lipid radical (a result of
electron extraction from polyunsaturated fatty acid by
hydroxyl radical) with molecular oxygen and an initiator of
lipid peroxidation within the cell membrane. Subsequently,
vitamin E is regenerated by vitamin C. Therefore, both
vitamin E and vitamin C help to cease the lipid peroxidation
chain reactions involving lipid peroxyl radicals [12]. GSH,
a major cellular redox buffer, can directly scavenge hydroxyl
radical and singlet oxygen. Through the action of GPx, GSH
can also remove H2O2 and lipid peroxides. Moreover, GSH
helps to regenerate both vitamin E and vitamin C back
to their active forms. Normally, a balance is maintained
between the levels of oxidants and antioxidants, which is
essential for survival.
During ischemic injury, there is overproduction of free
radicals that in turn leads to further production of radicals
through chain reactions [10, 12]. The imbalance between the
overproduction and scavenge of ROS/RNS leads to oxidative
stress/nitrosative stress. The excess ROS can damage cellular
lipids, proteins, or DNA and in turn inhibit their normal
function. ROS also disturbs normal functioning of mito-
chondria by opening the mitochondrial membrane perme-
ability transition pores (PTPs), leading to energy uncoupling
and further ROS production [13]. This also induces the
release of cytochrome c, leading to apoptosis [10, 14, 15].
In addition, superoxide reacts with NO to form ONOO
anion and in turn causes oxidation, lipid peroxidation,
and subsequently cellular damage [8]. Accumulation of
ONOO and free radicals in the nucleus also leads to DNA
damage [9]. Indeed, an increased level of nitrotyrosine, the
nitration product of ONOO, is observed after retinal ische-
mia/reperfusion (I/R) injury and is attributed to cell death
[16, 17].
Retinal ischemia is a common feature in ischemic reti-
nopathy such as diabetic retinopathy (DR) and retinopathy
of prematurity (ROP). In both ocular diseases, there is ini-
tially an impairment in the normal retinal blood supply while
the subsequent formation of abnormal new blood vessels
(retinal neovascularization) further worsens the condition.
The presence of ischemia and consequently oxidative stress
makes the already vulnerable retina more prone to oxidative
damage.
4. Oxidative Stress and the Pathogenesis of
Diabetic Retinopathy
DR is one of the major causes of blindness worldwide. Most
importantly, all patients with diabetes mellitus are at risk.
The longer the patient has diabetes, the higher the chance of
developing DR. As the total number of people with diabetes,
estimated to be 171 million worldwide in 2000 [18] is rising,
DR causes enormous economic and social burden to the
society. In particular, DR affects working-age adults. This
poses extra need and effort in treating the disease. Despite
extensive research, the promising therapeutics has yet to
come. Kowluru and Zhong have recently published an excel-
lent review in antioxidant therapy for age-related macular
degeneration (AMD) and DR, providing evidence on the
positive potential of antioxidant therapy clinical trials in DR
treatment [18] (Figure 1).
Basement membrane thickening, pericytes loss, microa-
neurysms, blood-retinal barrier breakdown, and neovascu-
larization are pathological features of DR [19].Microvascular
complication is a manifestation of DR which leads to retinal
ischemia/hypoxia and exacerbates the condition [20, 21].
Four major mechanisms are involved in development of
pathologies in DR: increased polyol pathway flux, increased
formation of advanced glycation end-products (AGEs),
activation of protein kinase C (PKC) isoforms, and increased
hexosamine pathway flux [22].
Increasing body of evidence shows that these metabolic
mechanisms are associated with excess production of ROS
and depletion of antioxidants in DR [19]. Firstly, aldose
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Figure 1: Schematic showing the relationship between oxidative
stress and DR. The four major mechanisms involved in DR:
increased polyol pathway flux, increased AGE formation, activation
of PKC pathway, and increased hexosamine pathway flux results
in I/R and increased production of ROS/RNS, thereby changing
the levels of JNK/p38 MAPK, PARP, and NFκB, increasing lipid
peroxidation as well as leading to mitochondrial dysfunction.
reductase (AR) is the first and rate-limiting enzyme in the
polyol pathway. In a hyperglycemic condition, AR reduces
glucose to sorbitol, consuming the cofactor NADPH. Sor-
bitol is then oxidized to fructose by the enzyme sorbitol
dehydrogenase. As NADPH is used for generating the
intracellular antioxidant GSH, a reduction in the availability
of NADPH exacerbates intracellular oxidative stress. The
increase in enzymatic activity of AR during hyperglycemia
further worsens the situation of DR [22, 23]. On the other
hand, inhibition of AR activity, either by specific inhibitor or
gene deletion, may have a therapeutic role in preventing the
progression of diabetic retinopathy [24–26] and ischemia-
related ocular diseases [21, 27, 28]. Application of the
AR inhibitor, fidarestat, is beneficial in decreasing the
concentrations of sorbitol and fructose and accumulation
of leukocytes in diabetic retina [24]. Secondly, AGEs and
its receptor, RAGE, can also cause oxidative stress. AGEs
induce oxidative damage by overproduction of superoxide
in neuronal culture through the activation of NADPH
oxidase in a PKCδ-dependent manner [29–31]. Increased
intracellular formation of AGE and RAGE activates a cascade
of signaling proteins and attributes to intracellular redox
imbalance, which leads to overproduction of ROS [29–
31]. On the other hand, inhibition of AGE formation and
suppression of the RAGE-mediated downstream pathway
have been suggested to be the feasible therapeutic strategies
for DR [32, 33]. In addition, hyperglycemia itself leads to
intracellular accumulation of glyceraldehyde-3 phosphate.
Glyceraldehyde-3 phosphate further induces the production
of ROS and leads to subsequent accumulation of poly(ADP-
ribose) polymerase-1 (PARP), which triggers the activation
of the PKC signaling pathway and increases AGE formation
[34]. Indeed, activation of PKC signaling pathway and over-
production of ROS by the mitochondria electron transport
chain are the key factors in the pathogenesis of DR [19, 23].
Oxidative stress causes the impairment of mitochondrial
function by damaging the inner membrane of mitochon-
dria, which leads to imbalance in the electron transport
chain and consequently leads to further overproduction of
superoxide, ONOO and hydroxyl radicals [35, 36]. Studies
have shown that ROS also impairs mitochondrial function
and transport machinery by damaging the mitochondrial
DNA and increases apoptosis of retinal capillary cells during
DR [37–39]. Increased ROS levels also trigger the release
of cytochrome c, which in turn damages the mitochondrial
membrane potential and initiate apoptosis by the activation
of caspase-9 and caspase-3 [40–43]. Apoptosis in DR is also
regulated by the family of Bcl-2 signaling proteins [43–45].
Several signaling pathways are involved in the patho-
genesis of DR. Mitogen-activated protein kinase (MAPK)
has been shown to play a role in hyperglycemia-induced
cell death in DR [46]. In a cell culture model of hyper-
glycemia and hypoxia, phosphorylation of c-Jun N-terminal
kinases (JNK) and p38 MAPK is induced, leading to
overproduction of ROS and disruption of tight junctions
in ARPE-19 cells [47]. In streptozotocin-induced diabetic
mice, activation of cannabinoid-1 receptor contributes to
DR by increasing MAPK activation, oxidative stress, and
inflammatory signaling [48]. In addition, PARP and nuclear
factor-kappa B (NFκB) are also downstream effectors of
oxidative stress. PARP is a DNA nick-sensor enzyme that
is activated by DNA single-strand breaks. It is involved in
DNA repair, gene transcription, cell death, and apoptosis
and acts as a coactivator in NFκB signaling pathway [34,
49, 50]. Increased levels of oxidative and nitrosative stress
induce DNA single-strand break and activates PARP. This
in turn inhibits the activity of GAPDH by poly(ADP-
ribosylation) and consequently leads to endothelial dys-
function in diabetic conditions [34]. Therefore, inhibition
of PARP could decrease the activation of PKC isoforms,
hexosamine pathway flux and AGE formation induced by
hyperglycemia [34]. As oxidative stress activates PARP, which
in turn initiates the activation NFκB, application of PARP
inhibitor could successfully inhibit hyperglycemia-activated
NFκB signaling pathway in endothelia cell culture [51]. Also,
inhibition of PARP or NFκB reduces the hyperglycemia-
induced cell death in retinal endothelial cells [50]. NFκB also
plays a role in apoptosis by triggering the Notch-1/Akt and
PI3k/Akt signaling pathways. Increased activation of PARP,
cleaved caspase-3 as well as reduced expression of Notch1
and pAkt have been observed, which consequently leads to
apoptosis in hyperglycemic retina [49].
5. Oxidative Stress and the
Pathogenesis of Retinopathy of
Prematurity (ROP)
Similar to DR, retinal ischemia/hypoxia is a feature in ROP,
which is a leading cause of blindness in children worldwide.
Retinopathy of prematurity (ROP) was first described as a
disease of prematurity [52, 53] and contributed to 50% of
infant blindness in 1950. The percentage dropped to 4% in
1965 after identification of supplemental oxygen use as a
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risk factor. Yet, with improved neonatal care and increased
survival of very low birth weight preterm infants the inci-
dence of ROP increased in recent years. ROP is now a major
cause of childhood blindness in developed and develop-
ing countries. Latest estimates from National Eye Institute
showed that 1,100–1,500 infants (∼5% infants ≤1.25 kg at
birth, <31 weeks of gestation) develop severe ROP that
requires treatment. Despite treatment, 400–600 infants (40%
with ROP, NIH figure) become legally blind. The resulting
long-term disability and severely affected quality of life in
ROP patients pose intense burden on the healthcare system
worldwide as the population ages, making ROP a major
public health issue.
ROP is an ocular disease characterized by vascular abnor-
malities induced by two phases of pathological changes. The
first phase starts with the cessation of retinal vessel growth
after premature birth. As premature infants are exposed to
high oxygen inside the incubator after birth, a condition
of relative hyperoxia happens, leading to downregulation of
vascular endothelial growth factor (VEGF) and a subsequent
regression of developed retinal vessels. After the cessation
of oxygen therapy, infants are returned to normal oxygen
tension and a condition of relative hypoxia occurs. In
addition, the metabolic demand of the relatively vascular-
depleted retina is now higher as the infant grows. Therefore,
the increased demand for oxygen poses a hypoxic injury
to the retina. The relatively hypoxic condition of the retina
triggers the abnormal proliferation of vessels and leads
to neovascularization; this is the second phase of ROP
progression [54]. Hypoxia-induced oxidative stress therefore,
plays a crucial role in the pathogenesis of ROP (Figure 2).
It has been shown that the production of enzymatic and
nonenzymatic antioxidants such as SOD, catalase, GPx, vita-
min C, and vitamin E increases dramatically in the late stage
of gestation [55, 56]. Yet, premature infants are born before
term; they are therefore, more susceptible to oxidative stress-
induced damage due to the inadequate levels of antioxidants
in premature birth and the inability of antioxidant synthesis
during the high-oxygen intensive care period [54]. Indeed,
the levels of 8-hydroxy 2-deoxyguanosine (8-OHdG), an
indicator of oxidative stress, in leukocyte and urine in ROP
infants are significant higher than the full-term infants,
confirming the presence of oxidative stress in ROP patients
[57].
During the two phases of ROP, the retina is subjected
to fluctuating oxygen tensions, resulting in retinal hypoxia
that triggers the overproduction of ROS, which activates
NADPH oxidase and attributes to intravitreal neovascu-
larization by the activation of signaling pathway such as
JAK/STAT [58, 59]. On the other hand, inhibition of
NADPH oxidase and JAK/STAT signaling pathway reduce
the level of cleaved caspase-3 and hence, apoptosis and
neovascularization in ROP retina [58, 59]. Increase intake
of omega-3-polyunsaturated fatty acids has been shown
to reduce the vaso-obliteration and neovascularization by
suppressing the TNF-α in ROP retina [60]. Antioxidants
such as vitamin E could also decrease the vaso-obliteration
I/R
ROS/RNS
JAK/STAT
Nitro-oxidation
(ONOO)
VEGF/IGF-1
ROP
Figure 2: Schematic showing the relationship of I/R, oxidative
stress, and ROP. I/R causes overproduction of ROS/RNS. The
resulting changes in levels of JAK/STAT, nitro-oxidation, and
VEGF/IGF-1 contribute to pathogenesis of ROP.
in ROP retina by its ROS scavenging property [61]. All this
evidence points to the importance of oxidative stress in the
pathogenesis of ROP.
Nitro-oxidation also contributes to the pathogenesis of
ROP. Increased level of NOS, which contributes to the
increase of NO production, is observed in neonatal retina
exposed to hypoxia [62]. In an animal model of ROP,
increased formation of ONOO and apoptosis of endothelial
cell were seen in association with increased tyrosine nitration
of PI3K, cleaved caspase-3, activation of p38MAPK signaling
pathway, and decreased Akt phosphorylation. However,
blocking tyrosine nitration of PI3K with epicatechin or N-
acetylcysteine reverses the nitro-oxidation-induced patho-
genesis [63]. In addition, application of NOS inhibitor or
gene deletion of endothelial NOS effectively reduces the
severity of ROP in mice, indicating the crucial role of nitro-
oxidative stress in ROP [64]. Moreover, melatonin adminis-
tration reduces the production of VEGF and NO as well as
promotes cell proliferation, consequently reducing hypoxia-
associated retinopathy [62].
VEGF signaling is a dominant pathway involved in the
hypoxia-induced neovascularization and retinopathy in
ROP. In the retina, VEGF is primarily secreted byMuller cells
and astrocytes. In phase II of ROP, relative hypoxia induces
VEGF production and hence promotes pathological vessel
proliferation [65, 66]. IGF-1 is another determining factor
in the pathogenesis of ROP and is critical in normal retinal
vessel growth. IGF-I is a permissive factor of VEGF activation
of Akt survival signaling in the growth of endothelial cells in
phase I of ROP [67]. In preterm infants after birth, lower
levels of IGF-I reduce Akt activation and endothelial cell
survival, whichmakes thematuring avascular retina becomes
hypoxic and leads to accumulation of VEGF in the vitreous
[67]. IGF-1 level rises with high levels of VEGF, which
triggers neovascularization through the activation of MAPK
and Akt signaling pathways in phase II of ROP [67, 68].
Inhibition of IGF-1 and VEGF are capable to hinder the
neovascularization.
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6. Antioxidants in Ischemic Retinopathies
DR and ROP are blinding disorders that affect working-age
adults and premature infants, causing enormous burden on
the society. Yet, the treatment options are limited to laser
photocoagulation and anti-VEGF therapy. Pathologically,
they both follow a similar pattern as in ischemic retinopathy.
As oxidative stress play a pivotal role in the pathogenesis of
ischemic retinopathy, agents that can reduce the formation of
ROS or increase the antioxidant mechanisms to counteract
oxidative stress are beneficial to the situation. Examples of
some of these agents are discussed below.
Catalase and SOD are potent ROS scavengers to block
oxidative stress in the retina. SOD catalyzes the conversion
of superoxide to oxygen and H2O2 while catalase prevents
the formation of hydroxyl radical resulting from the reaction
of H2O2 and ferrous ions [69]. Gene transfer of plasmids
encoding MnSOD or catalase complexed with liposomes
reduces apoptosis of retinal vascular cell and prevents retinal
degeneration induced by retinal I/R [69]. In addition, pre-
treatment of intravitreal recombinant adenoassociated virus
containing the catalase gene (AAV-CAT) efficiently increases
the catalase activity and decreases the levels of H2O2, 8-
OHdG and nitrotyrosine as well as attenuates the I/R-
induced retinal function loss, suggesting the beneficial effects
of catalase in ischemia/reperfusion-related eye diseases by
reducing oxidative stress [70].
As discussed earlier, nitrosative stress also causes detri-
mental damages during retinal ischemia. NADPH oxidase
catalyzes the formation of superoxide from oxygen and
NADPH. In ischemic injury in mice, gene deletion of
NADPH oxidase reduces the production of ROS, retinal cell
loss and glial cell activation, together with an inhibition in
the activation of extracellular-signal-regulated kinase (ERK)
and NFκB signaling pathways [71]. Moreover, blockade of
astrocytic NFκB signaling or administration of NADPH oxi-
dase inhibitors reduces retinal ganglion cell death cocultured
with astroglia under hypoxia [72]. Gene deletion of astroglial
NF-κB also reduced oxidative stress in retinal I/R in mice
[72, 73]. Most importantly, inhibition of NFκB activation
by either gene deletion of NADPH oxidase or application of
apocynin reduced the retinopathy in ROP and DR animal
models [74].
Edaravone is a free radical scavenger which directly scav-
enges hydroxyl radical and inhibits lipoxygenase activity
[75]. It has been shown that application of edaravone can
reduce oxidative stress-induced damage by lowering the lev-
els of malondialdehyde (MDA), raising enzymatic activity of
SOD, reducing apoptosis of retinal neurons, and preventing
retinal functional deterioration in retinal I/R [76]. This
suggests that edaravone protects the eye from I/R injury and
may carry therapeutic potential in treatment of I/R-induced
eye disorders.
Vitamin E is well known to have potent anti-oxidative
properties in ocular disease related to retinal I/R, including
ROP and diabetic retinopathy [77–81]. It is a lipid peroxyl
radical scavenger via breaking the lipid peroxidation chain
and acts against oxidative stress [77–81]. In an animal model
of retinal I/R injury, reduced levels of oxidative stress marker
such as MDA together with an inactivation of caspase-3
but increased levels of GSH were noted with vitamin E
treatment [77–81]. In experimental DR models, oral intake
of antioxidants, including vitamin E, significantly reduced
lipid peroxidation and arrested retinal abnormalities in
streptozotocin (STZ)-induced diabetic rats [82]. Intake of
micronutrients based on the AREDS formula (vitamin E,
ascorbic acid, beta-carotene, zinc, and copper) inhibited the
increases in nitrotyrosine and inducible NOS and decreases
in MnSOD in STZ-induced diabetic rats [83]. In ROP mod-
els, vitamin E can reduce the area of vaso-obliteration [61,
84], preserve retinal function [85] and protect the reduction
of outer plexiform thickness [86]. Most importantly, vitamin
E supplementation decreased the risk of severe retinopathy
and blindness in very low birth weight infants [81]. All this
evidence points to a beneficial role of vitamin E in ischemic
retinopathy.
Numerous studies have investigated the role of erythro-
poetin (EPO) in ischemic retinopathy. EPO is a glycoprotein
hormone that is involved in the pathogenesis of ROP. EPO
level decreases and contributes to vessel obliteration in phase
I of ROP; therefore, early administration of exogenous
EPO minimizes vessel obliteration and subsequent hypoxia-
induced neovascularization and neuron apoptosis by the
activation of prosurvival NFκB signaling pathway via the
EPO receptor [87]. However, the level of EPO mRNA
increases during the neovascularization phase when late
EPO application promotes pathologic neovascularization
[87]. In addition, increased level of VEGF leads to vaso-
obliteration by suppression EPO expression through the
Janus kinase/STAT signaling pathway. Application of exoge-
nous EPO inhibits the activation of STAT3 and hence,
reduces the area of vaso-obliteration and consequently
neovascularization in phase II of ROP [88]. Furthermore,
administration of EPO siRNA suppresses neovascularization
during phase II of ROP. Therefore, the time of exogenous
treatment/inhibition is very critical to the prevention of
ROP pathogenesis [89]. Similarly, EPO also exerts its anti-
oxidative and protective effects in DR. Low-dose EPO
inhibits oxidative stress and nitro-oxidative stress in exper-
imental diabetic retina by reducing Ang-2 expression and
pericyte loss as well as restoring pAkt and heat shock
protein-27 levels [90]. In addition, EPO therapy decreases
the formation of acellular capillaries and the loss of pericytes,
which prevents the early vascular changes in DR [90].
EPO treatment also decreases VEGF levels and protects
microvascular and neuronal damage in the experimental
diabetic retina [91].
Lutein is a member of xanthophyll family of carotenoids
and is contained in dark green leafy vegetables, such as
spinach and kale [92–94]. It is a powerful anti-oxidant due to
its unique chemical structure. It is characterized by having a
hydroxyl group attached to each end of the molecule, making
it more hydrophilic, and therefore, lutein reacts more strong-
ly with singlet oxygen than other carotenoids [95, 96].
Increasing evidence has shown that lutein is neuroprotective
in retinal I/R injury. We show that lutein prevents the
increase of nitrotyrosine and PAR and hence, apoptosis and
cell loss in inner retinal neuron in an animal model of retinal
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I/R [16]. We further show that lutein can directly protect
RGC fromH2O2-induced oxidative stress and cobalt chloride
(CoCl2)-induced hypoxia in vitro [97]. In retina of diabetic
mice, lutein reduces the production of ROS, inactivates
the NFκB signaling pathway, and decreases the levels of
oxidative markers, thereby preserving the retinal function
[98]. Lutein also prevents ERK activation, synaptophysin
reduction, BDNF depletion, and consequently neuronal loss
in the diabetic retina [99]. However, supplementation of
anti-oxidants, including lutein, is ineffective in preventing
ROP in preterm infants [100, 101]. Yet, the protective effects
of lutein in ROP are still debatable due to the complicated
pathogenesis of ROP.
7. Future of Antioxidant Treatment in
Ischemic Retinopathy
DR and ROP are two examples of ischemic retinopathy. As
mentioned earlier, DR and ROP are blinding disorders that
affect working-age adults and premature infants, respec-
tively. The subsequent long-term disability and poor quality
of life pose enormous burden on the society. Much research
has been conducted, but with no satisfactory outcome.
As discussed by Kowluru and Zhong [18], there are seri-
ous challenges although promising results are observed in
experimental DR models. Firstly, rodents only display the
early retinopathy stages but not the later changes seen in
patients with diabetic retinopathy. Secondly, DR is a complex
diabetic complication; identification of the best molecular
pathway for targeted therapeutic studies is not easy. Yet, the
administration of the AREDS formula containing various
antioxidants to diabetic rats has provided a significant step
forward for antioxidant treatment for DR [83].
In ROP, lutein, vitamin E and EPO have all shown hope-
ful results in experimental models. Similar to the negative
results in antioxidant therapy in DR, lutein is not able to
yield beneficial effects in two randomized controlled clinical
studies [100, 101]. However, vitamin E and EPO have
shown some promising outcomes clinically. An early meta-
analysis concluded that there is a 52% reduction in the
incidence of Stage 3+ ROP with vitamin E prophylaxis in
extremely low birth weight (<1000 gm) infants [80]. In a later
clinical study, it is concluded that vitamin E is proven to be
effective in prophylaxis of ROP development, and vitamin
E supplementation relates to lower incidence of ROP [102].
Recently, interventions such as increasing retinal EPO and
vitamin E supplements have been suggested [103]. Although
well-designed randomized clinical trials are necessary before
these interventions can be put into clinical practice, they have
provided strong evidence that antioxidant therapy does have
a potential role in treatment of ROP.
8. Conclusion
Hypoxia-induced oxidative stress leads to irreversible retinal
damage in ocular diseases in which retinal ischemia is a
feature. Treatments that can decrease the production of ROS
or increase the ROS scavenging ability of the system may
be beneficial to the situation. The positive outcomes in
administration of AREDS antioxidants in DR experimental
models as well as EPO and vitamin E supplements in ROP
infants have strongly indicated the potential efficacy of
antioxidant in treating ischemic retinopathy with hypoxia-
induced oxidative stress.
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8-OHdG: 8-hydroxy 2-deoxyguanosine
AGE: Advanced glycation end-product
AMD: Age-related macular degeneration
AR: Aldose reductase
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